Immunomonitoring of Breast Cancer Patients During Systemic Treatment

This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe the basal immune response of patients treated for a breast cancer according to the stage of the disease, but above all to study how the different systemic treatments used in the management of breast cancer modulate this immune response.

Trial Details

NCT ID
NCT04925856
Phase
NA
Sponsor
Centre Georges Francois Leclerc
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • blood sample
Locations (sample)
  • Besançon, France|47.24878,6.01815
  • Dijon, France|47.31344,5.01391

Key Eligibility Criteria

  • Woman aged between 18 and 85.
  • Patient with histologically proven infiltrating breast cancer.
  • Triple negative breast cancer or RH + / HER2- (OR and RP \<10% and HER2 negative (0 or 1+ in IHC or 2+ in IHC and FISH negative)
  • Patient receiving treatment corresponding to one of these cohorts:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →